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Abstract
Purpose Motesanib (AMG 706) is a multitargeted anti-
cancer agent with an inhibitory action on the human vascu-
lar endothelial growth factor receptor, the platelet-derived
growth factor receptor, and the cellular stem-cell factor
receptor (KIT). The aim of this single-arm phase II clinical
study was to assess the eYcacy and safety of single-agent
motesanib in Japanese patients with advanced gastrointesti-
nal stromal tumors with prior exposure to imatinib
mesylate.
Methods All patients had experienced progression or
relapse while undergoing with imatinib as 400 mg/day or
higher. The patients were administered 125 mg of motesa-
nib once daily. The primary endpoint was overall response.
EYcacy was evaluated according to the Response Evalua-
tion Criteria in Solid Tumor, and safety was assessed
according to the Common Terminology Criteria for
Adverse Events (version 3).
Results Of 35 enrolled and treated patients, no patient
showed a complete response, and one patient showed a par-
tial response (PR). Seven had stable disease (SD) for at
least 24 months, two of whom continued to have SD for
more than 2 years. The median progression-free survival
time was 16.1 weeks. Motesanib was well tolerated; com-
monly reported treatment-related adverse events were
hypertension, diarrhea, and fatigue. Anemia was the only
hematological toxicity that was reported.
Conclusions One patient showed PR, and seven patients
showed SD more than 24 weeks. Motesanib was found to
be safe and well tolerated. The observed toxicities were
consistent with Phase I study Wndings.
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Introduction
Gastrointestinal stromal tumor (GIST) is a rare stromal
neoplasm that predominantly arises from the muscularis
propria layers, representing the most common mesenchy-
mal tumor of the gastrointestinal tract. Although the pri-
mary therapy for nonmetastatic GIST is surgical resection,
there still remain unresectable cases of advanced or meta-
static GIST. Unresectable GISTs are resistant to conven-
tional chemotherapy and radiotherapy [1]. Before imatinib
mesylate was introduced in clinical practice, the prognosis
for patients with unresectable GIST was dismal, with a
median survival period of 22 months [2].
The critical transforming and oncogenic mechanisms of
GISTs are activating mutations in the stem-cell factor
receptor, KIT tyrosine kinase [3]. About 5% of GISTs are
caused by activating mutations of the platelet-derived
growth factor receptor alpha (PDGFRA), and are indepen-
dent of c-kit mutations [4]. The c-kit and PDGFRA muta-
tions appear to be alternative and mutually exclusive
oncogenic mechanisms in GIST.
Imatinib mesylate blocks the constitutively activated
form of KIT in GISTs, and has dramatically improved the
outcome for patients with unresectable GIST [5]. Treatment
with imatinib mesylate results in partial response (PR) or
stable disease (SD) in approximately 80% of patients with
advanced or metastatic GIST [6], and the 2-year survival
rate of these patients is reported to be 70% [7].
However, approximately 10–15% of advanced GIST
patients will suVer a progressive disease (PD) despite treat-
ment with imatinib mesylate. Many of the patients who ini-
tially responded to imatinib mesylate therapy experience tumor
progression after an average of 2 years of treatment [7, 8].
Sunitinib is an orally administered receptor tyrosine
kinase (RET) inhibitor that targets multiple kinases and is
used as a second-line treatment for patients with imatinib-
resistant or -intolerant GIST. A Phase III double-blind, pla-
cebo-controlled trial comparing sunitinib with placebo
showed that the time to progression was signiWcantly
longer in the sunitinib group than in the placebo group (6.3
versus 1.5 months). Adverse reactions, though observed,
were acceptable [9]. However, despite initial response or
stabilization, the disease developed resistance in most
patients after approximately 7 months. Because no thera-
pies are available for patients with GIST once imatinib and
sunitinib fail, there exists a need for alternative agents that
block the signaling pathways in GIST cells.
Motesanib is a novel, synthetic, small molecule that
strongly and selectively inhibits vascular endothelial
growth factor receptors 1, 2, and 3, as well as the cellular
KIT, the platelet-derived growth factor receptor (PDGFR),
and the glial-derived nerve growth factor family ligand
RET. The safety and pharmacokinetic (PK) proWle of
motesanib were evaluated in a Phase I, monotherapy, open-
label, dose-Wnding study [10]. In this study, motesanib
showed clinical activity in patients with advanced refrac-
tory solid tumors; SD was observed in a signiWcant propor-
tion of the patients, although the overall tumor response
rate was low.
The above Wndings prompted us to conduct a Phase II
study to evaluate the eYcacy, safety, and PK of motesanib
in Japanese patients with advanced GIST, after failure or
withdrawal of imatinib mesylate due to resistance or intol-
erance.
Materials and methods
Patients
Japanese patients with pathologically conWrmed advanced
or metastatic GIST were eligible for this study if they met
the following criteria; age ¸ 20 years; a proven KIT posi-
tive or activating mutation of PDGFR; prior imatinib mesy-
late therapy of 400 mg/day or more for at least 8 weeks;
disease progression or relapse while on previous treatment
with imatinib mesylate; at least one tumor lesion measur-
able by a computed tomographic (CT) scan or magnetic
resonance imaging (MRI); an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (PS) of 0 to 2; a life
expectancy of more than 3 months; adequate organ func-
tions as deWned by: neutrophils ¸1.5 £ 103 cells/mm3,
platelets  ¸1.0 £ 104 cells/mm3, hemoglobin ¸9.0 g/dl,
serum creatinine ·2.0£ upper limit of normal (ULN),
urine protein quantitative value of ·1+ on dipstick or
30 mg/dl in urinalysis, aspartate aminotransferase
·2.5 £ ULN (5.0 £ ULN in patients with liver metastasis),
alanine aminotransferase ·2.5 £ ULN (5.0 £ ULN in
patients with liver metastasis), alkaline phosphatase
·2.5 £ ULN (5.0 £ ULN in patients with bone or liver
metastasis), and total bilirubin ·2.0 £ ULN. This protocol
was approved by the Institutional Review Board at each
study site. All patients provided written informed consent.
Study design
This study was an open-label and multicenter Phase II clin-
ical study. The primary endpoint was the objective response
rate to a once daily oral treatment with 125 mg motesanib
in patients with advanced GISTs who experienced disease
progression or relapse while on imatinib mesylate treat-
ment. (Sunitinib was not approved for imatinib-resistantCancer Chemother Pharmacol (2010) 65:961–967 963
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GIST until 2 years after their study was completed.) The
secondary endpoints were duration of response, progres-
sion-free survival (PFS), time to response, overall survival,
and PK proWles of motesanib in Japanese patients with
advanced GISTs.
The dose was Wrstly reduced to 100 mg, and if need be,
to 75 mg in the second time. If the grade 3 adverse event
(AE) is not adequately controlled with appropriate support-
ive care or a grade 4 AE occurs, motesanib was withheld.
Once the grade 3 or 4 AE has resolved to baseline or grade
·1 for nonhematologic toxicities or baseline or grade ·2
for hematologic toxicities, the dose was reduced by 25 mg
and treatment was resumed. If treatment with motesanib
was withheld for >21 days, the patient should be withdrawn
from the treatment period and complete the end of study
procedures. If a patient was receiving 75 mg and requires a
dose reduction, treatment with motesanib was stopped and
the patient should complete the end of study procedures.
Tumor evaluation was performed after 8 weeks and at
every 8 weeks thereafter, by using the modiWed Response
Evaluation Criteria in Solid Tumor (RECIST). A conWrma-
tion of tumor response was performed by using the modiWed
RECIST at least 4 weeks after a complete response (CR) or
PR was Wrst documented. An appointed radiographic image
reviewer who was independent of the study site or the study
sponsor reviewed CT or MRI of all patients.
The severity of AEs was graded according to Common
Toxicity Criteria for Adverse Events (CTCAE, version 3).
Special attention was paid to cardiac function, hyperten-
sion, hypothyroidism, and cholecystitis. Laboratory assess-
ments (serum chemistry, hematology, thyroid hormones,
blood pressure, and electrocardiogram) were performed
every 2 weeks.
Ten patients had the following PK parameters: maxi-
mum observed plasma concentration (Cmax), terminal elimi-
nation half-life (t1/2), area under the plasma concentration–
time curve from time 0 to 24 h after dosing (AUC0–24), con-
centration at 24 h after dosing (C24), maximum plasma con-
centration time (tmax), the area under the plasma
concentration versus time curve from 0 to inWnity (AUC0–inf),
and apparent plasma clearance (CL/F). These PK
parameters of motesanib were calculated by the standard
noncompartmental model using WinNonlin software ver-
sion 4.1e (Pharsight Corporation, Mountain View, CA,
USA) and summarized according to the study day and his-
tory of gastrectomy using descriptive statistics. Individual
plasma concentration–time proWles were summarized by
history of gastrectomy.
Statistical analysis
Descriptive statistics are provided for each endpoint. The
safety analysis population consisted of all patients who
received at least one dose of motesanib. The objective
response rate and its two-sided 95% conWdence interval
(95% CI) were calculated. The CI was constructed by the
exact method described by Collett [10]. For a PFS, calcu-
lated as the number of days between the Wrst dose of
motesanib and the date when radiological evidence of dis-
ease progression is determined (date of CT scan/MRI), or
death (regardless of cause), whichever comes Wrst (date of
PD or death minus date of Wrst dose of motesanib), Kaplan–
Meier curve (with two-sided 95% CI) was generated and its
standard error was calculated using Greenwood’s formula.
Statistical analyses were performed using the SAS statistical
software package (SAS Institute Inc., Cary, NC, USA) [11].
Results
Patient population
A total of 35 patients were enrolled and treated with
motesanib between November 2005 and June 2006 at the
following sites: Aichi Cancer Center Hospital, Osaka Uni-
versity Hospital, National Cancer Center Hospital, Hokka-
ido University Hospital, Niigata University Hospital,
National Cancer Center Hospital East, National Hospital
Organization Kure Medical Center, and Kumamoto Univer-
sity Hospital. One patient did not undergo baseline CT
assessment. Hence, 34 patients were eligible for tumor
response evaluation, and 35 for toxicity evaluation. Base-
line demographic and clinical characteristics are summa-
rized in Table 1. Of the 35 patients enrolled, 17 (49%) were
female and the median age was 62.0 years (range 31–
83 years). Every patient was diagnosed as having GIST
with positive immunoreactivity for KIT protein. The most
common primary sites of the tumor were the small intestine
(n = 17) and the stomach (n = 10). The other sites of the
tumor were the colon (n = 2) and the rectum (n =2 ) .  A l l
patients had received treatment with imatinib mesylate but
not with other tyrosine kinase inhibitors. The mean time
from the last imatinib treatment was 0.9 months (range
0.2–5.5 months).
Outcome measures
The tumor response as assessed by an independent radio-
graphic image reviewer is shown in Table 2. No CR was
observed among the 35 patients enrolled in this study. One
patient (3%; 95% CI 0.1–14.9%) had a PR and seven
patients (20%) demonstrated SD for at least 24 months, two
of whom continued to have SD for more than 2 years.
Twelve additional patients had SD lasting for 12 weeks or
more. Thirteen patients experienced disease progression
within 12 weeks. The patient with PR had a gastric GIST964 Cancer Chemother Pharmacol (2010) 65:961–967
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with spindle-cell type, exon 11 mutation, liver, and perito-
neal metastases, and had initially responded to imatinib
with SD as assessed by RECIST (Fig. 1). The median PFS
time of motesanib was 16.1 weeks (95% CI 8.4–
32.0 weeks; Fig. 2).
Safety and tolerability
Table 3 summarizes treatment-related adverse events
(TRAEs) (patient incidence ¸15%). The most frequent
nonhematologic TRAEs included hypertension (63% of
patients), diarrhea (51%), and fatigue (43%). Five patients
(14%) experienced grade 3 hypertension and two patients
(6%) experienced grade 3 fatigue. The only hematological
toxicity was anemia (grade 2 in 3% of patients, grade 3 in
6% of patients, and grade 4 in 0% of patients). One patient
(3%) experienced grade 4 hyperuricemia. No grade 5
TRAEs occurred.
Previous motesanib studies have reported an increased
occurrence of cholecystitis in patients receiving motesanib,
Table 1 Baseline characteristics
All patients (N =3 5 )
Sex, n (%)
Female 17 (49)
Male 18 (51)
Age
Median 62.0
Min, max 31, 83
Age group, n (%)
<65 years 23 (66)
¸65 years 12 (34)
¸75 years 4 (11)
ECOG PS, n (%)
0 24 (69)
19  ( 2 6 )
22  ( 6 )
Site of primary tumor at diagnosis, n (%)
Small intestine 17 (49)
Stomach 10 (29)
Colon 2 (6)
Rectum 2 (6)
Table 2 Best tumor response per modiWed RECIST per independent
review
Full analysis set includes all patients who received at least one dose of
motesanib
a Patients with a response assessment of PR or CR that is not subse-
quently conWrmed at least 4 weeks later are included as SD
b Unevaluable includes patients with a response assessment of CR,
PR, or SD prior to the scheduled Wrst assessment of response without
an additional assessment of response
c Binomial proportion with exact 95% CI
d Durable SD is deWned as having a best response on study as SD with
a duration of ¸24 weeks from study day 1
All patients 
(N = 35)
Patients with measurable disease at baseline 34 (97)
Response assessment, n (%)
ConWrmed CR 0 (0)
ConWrmed PR 1 (3)
SDa 19 (54)
PD 13 (37)
Unevaluableb 1 (3)
Not done 1 (3)
ConWrmed objective response (CR or PR) 1 (3)
95% CIc 0.1–14.9
Durable SDd 7 (20)
Fig. 1 A 68-year-old male with a primary GIST of the stomach and
recurrent liver and peritoneal metastases. a Pre-treatment CT scan
shows multiple low-density masses. b CT scan obtained after 3 months
of treatment with once daily motesanib 125 mg shows that the multiple
lesions have become signiWcantly smaller and less denseCancer Chemother Pharmacol (2010) 65:961–967 965
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speciWcally at a dose of 75 mg twice daily continuously.
The etiology of cholecystitis observed in patients receiv-
ing motesanib is unknown. Cholecystitis was not
reported in this study. Gallbladder disorder was reported
in three patients, speciWcally extended gallbladder or
wall thickening, which was incidentally discovered in
these patients on ultrasound sonography (US). The
patients had not undergone US before starting motesanib
treatment, nor were these disorders detected on routine
CT scanning.
Figure 3 and Table 4 summarize the results of the inten-
sive PK analyses. After a single-dose oral administration
of 125 mg on day 1, motesanib was rapidly absorbed, with
an overall median tmax of 0.75 h; a similar median tmax
value (0.79 h) was observed after daily administration of
motesanib on day 29. The mean Cmax, AUC0–24, and C24
were slightly lower on day 29 than on day 1, indicating
that there was no accumulation after daily administration.
The day 29 to day 1 mean ratios were 0.62, 0.71, and 0.80
for Cmax, AUC0–24, and C24, respectively, for all evaluable
patients.
Fig. 2 Kaplan–Meier estimates 
of PFS
Table 3 TRAE (15% or more 
of the patients)
Preferred term Number of patients 
reporting TRAE, n (%), 35 (100)
All patients 
(N =3 5 )
Grade 1/2 Grade 3 Grade 4 All grades
Anemia 1 (3) 2 (6) 0 (0) 3 (9)
Hypertension 17 (48) 5 (14) 0 (0) 22 (63)
Diarrhea 18 (51) 0 (0) 0 (0) 18 (51)
Fatigue 13 (38) 2 (6) 0 (0) 15 (43)
Headache 11 (31) 0 (0) 0 (0) 11 (31)
Weight decreased 11 (31) 0 (0) 0 (0) 11 (31)
Rash 10 (29) 0 (0) 0 (0) 10 (29)
Anorexia 5 (14) 4 (11) 0 (0) 9 (26)
Nausea 8 (23) 1 (3) 0 (0) 9 (26)
Blood thyroid-stimulating 
hormone increased
8 (23) 0 (0) 0 (0) 8 (23)
Dysphonia 8 (23) 0 (0) 0 (0) 8 (23)
Protein urine present 6 (17) 1 (3) 0 (0) 7 (20)
Dry skin 6 (17) 0 (0) 0 (0) 6 (17)
Vomiting 5 (15) 1 (3) 0 (0) 6 (17)
Fig. 3 Mean concentration–time proWles after oral administration of
125 mg of motesanib on day 1 in patients without gastrectomy and in
patients with partial or full gastrectomy966 Cancer Chemother Pharmacol (2010) 65:961–967
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For the patients who had partial or full gastrectomy
(n = 4), day 1 Cmax values were slightly higher (<2-fold)
and AUC values were similar to those who had no gastrec-
tomy. Means for Cmax and AUC values on day 29 were
higher compared with those who had no gastrectomy but
not signiWcant. Median tmax values occurred earlier in
patients with gastrectomy on both days 1 and 29 (median
tmax = 0.50 h with gastrectomy versus 1.0 h with no gastrec-
tomy). C24 values on days 1 and 29 were lower in patients
with gastrectomy compared with those who had no gastrec-
tomy, though the mean t1/2 values were similar (mean t1/2,z
value = 4.22 versus 4.32 h, respectively).
Discussion
Although regression of thyroid cancer, renal cell carcinoma,
and leiomyosarcoma was observed in the Phase I study of
motesanib [12], objective tumor regression was observed in
only one patient (3%) with GIST in this study. Motesanib
administered as a single-agent was well tolerated, and a num-
ber of patients experienced prolonged stabilization of the dis-
ease. Seven (20%) did not exhibit disease progression for a
minimum of 24 weeks, and the median PFS was 16.1 weeks.
Serious hematological AEs (grade 3/4) were observed after
sunitinib treatment in the Phase III trial. The incidence of grade
Table 4 Summary of PK parameters following oral administration of 125 mg motesanib on days 1 and 29
Note: One patient did not have intensive sampling for day 29. This patient was excluded from the summary statistics
Parameters are presented to three signiWcant Wgures when possible. Ratios are presented to two decimal places
Patients with elevated motesanib concentrations at 24 h post-dose were excluded from the C24, t1/2, AUC, and AUC-derived parameter summary
statistics calculations, hence the reduced sample size for these parameters
tmax = the time the maximal plasma concentration was observed; Cmax = the maximal observed plasma concentration after dosing; AUC0–24 =t h e
area under the plasma concentration–time curve from time 0 to 24 h post-dose; AUC0–inf = the area under the plasma concentration–time curve
from time 0 to inWnite time; t1/2,z = estimated terminal-phase half-life; CL/F = apparent clearance (AUC0–24 was used to estimate CL/F on day 29);
C24 = the observed plasma concentration at 24 h after dosing; NA not applicable
a tmax is reported as a median (range) value, and is presented to two signiWcant Wgures
b One patient had a C24 ratio of 3.84. The C24 ratio (mean § SD) excluding this patient is 0.42 § 0.30 for all patients and 0.43 § 0.42 for patients
without gastrectomy
PK parameter N Day 1
Mean § SD
Day 29
Mean § SD
Day 29:Day 1 ratio
Mean § SD
All evaluable patients
tmax (h)a 10 0.75 (0.25–2.0) 0.79 (0.50–4.0) NA
Cmax (ng/ml) 10 800 § 439 488 § 363 0.62 § 0.20
AUC0–24 (g h/ml) 9 3.87 § 2.28 2.51 § 2.10 0.71 § 0.32
AUC0–inf (g h/ml) 9 4.14 § 2.47 NA NA
t1/2,z (h) 8 5.42 § 1.51 4.27 § 1.26 NA
CL/F (l/h) 9 41.1 § 22.3 69.3 § 31.8 NA
C24 (ng/ml) 9 27.6 § 23.8 12.9 § 15.4 0.80b § 1.17
Evaluable patients with no prior gastrectomy
tmax (h)a 6 1.0 (0.25–2.0) 1.0 (0.50–4.0) NA
Cmax (ng/ml) 6 692 § 312 354 § 193 0.53 § 0.16
AUC0–24 (g h/ml) 5 3.91 § 2.43 1.93 § 0.67 0.67 § 0.39
AUC0–inf (g h/ml) 5 4.27 § 2.73 NA NA
t1/2,z (h) 4 5.20 § 1.79 4.32 § 1.89 NA
CL/F (l/h) 5 40.7 § 24.5 71.5 § 26.0 NA
C24 (ng/ml) 5 33.5 § 31.1 16.6 § 20.3 1.11b § 1.57
Evaluable patients with partial or full gastrectomy
tmax (h)a 4 0.50 (0.25–2.0) 0.50 (0.50–1.0) NA
Cmax (ng/ml) 4 962 § 599 689 § 492 0.75 § 0.21
AUC0–24 (g h/ml) 4 3.82 § 2.45 3.23 § 3.16 0.75 § 0.25
AUC0–inf (g h/ml) 4 3.99 § 2.49 NA NA
t1/2,z (h) 4 5.63 § 1.42 4.22 § 0.38 NA
CL/F (l/h) 4 41.6 § 22.9 66.4 § 42.2 NA
C24 (ng/ml) 4 20.2 § 9.2 8.37 § 6.24 0.40 § 0.16Cancer Chemother Pharmacol (2010) 65:961–967 967
123
3/4 anemia, leukocytopenia, and neutrocytopenia was 4, 4, and
10%, respectively [9]. Anemia, leukocytopenia, and neutrope-
nia were also reported as AEs for patients treated with imati-
nib; the incidence of grade 3/4 anemia, leukocytopenia, and
neutropenia in a large Phase III study was 2.0, 1.4, and 4.8%,
respectively [6]. The only hematological toxicity of motesanib
was anemia (grade 2, 3%; grade 3, 6%). Despite long-term
exposure to motesanib, hematological toxicities were mild.
Motesanib may therefore present an alternative treatment
option for patients who experienced neutrocytopenia or throm-
bocytopenia after treatment with imatinib or sunitinib.
To evaluate the potential eVect of gastrectomy on motesa-
nib disposition, the motesanib PK proWles from patients with a
history of gastrectomy were compared with those who did not
have prior gastrectomy. Median tmax values occurred earlier in
patients with gastrectomy on both days 1 and 29, suggesting
faster absorption in patients with a history of gastrectomy.
Since gastrectomy impacts the gastric emptying rate and the
absorption rate resulting in increase in Cmax, these Wndings
should be considered in the following clinical trials.
The current treatment options for patients with GIST after
treatment failure with imatinib and sunitinib are limited to
best supportive care and investigative therapies. This study
shows that in Japanese patients with advanced GIST motesa-
nib is well tolerated, and, although an objective tumor
response was observed in only one patient, motesanib may
have an impact on survival in a retrospective analysis. How-
ever, focusing on other clinically meaningful measures, such
as the Choi criteria [13] that incorporating tumor density and
small changes in tumor size as revealed by CT scanning, is
more important than focusing on the tumor response rate,
which may fail to identify a potentially eVective therapy [14,
15]. Randomized, well-controlled studies with time to pro-
gression or survival as the primary endpoints of eYcacy will
be needed to identify agents for which a tumor regression
eVect is not anticipated. Results from such studies will help
in making an informed decision of whether or not to continue
the clinical development of such agents in GIST.
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